Guided Therapeutics (GTHP) Total Liabilities (2010 - 2026)

Guided Therapeutics has disclosed Total Liabilities across 17 years of filings, most recently posting $7.0 million for Q2 2026.

• In Q2 2026, Total Liabilities rose 8.52% year-over-year to $7.0 million; the TTM figure through Jun 2026 stood at $7.0 million (up 8.52% YoY), while the FY2025 annual figure was $7.3 million, up 16.96% from the prior year.
• Total Liabilities came in at $7.0 million for Q2 2026 at Guided Therapeutics, up from $6.8 million in the prior quarter.
• In the past five years, Total Liabilities ranged from a high of $7.3 million in Q4 2025 to a low of $5.5 million in Q4 2023.
• Average Total Liabilities over 5 years is $6.3 million, with a median of $6.3 million recorded in 2022.
• Year-over-year, Total Liabilities plunged 30.31% in 2022 and increased 16.96% in 2025.
• Over 5 years, Total Liabilities stood at $6.2 million in 2022, then declined by 12.39% to $5.5 million in 2023, then gained by 14.47% to $6.3 million in 2024, then increased by 16.96% to $7.3 million in 2025, then dropped by 5.08% to $7.0 million in 2026.
• Per Business Quant data, the three most recent Total Liabilities figures were $7.0 million in Q2 2026, $6.8 million in Q1 2026, and $7.3 million in Q4 2025.